Anzeige
Mehr »
Donnerstag, 12.02.2026 - Börsentäglich über 12.000 News
Drohnen, Robotik, E-Autos: Diese Hightech-Aktie könnte jetzt zünden
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
25 Leser
Artikel bewerten:
(0)

Merck Introduces Spectroquant Prove Family of System Spectrophotometers for Simplified, Durable and Secure Water Analysis


-- Applications include waste water, drinking water, beverages and process water

-- Offers the largest choice of water test kits with Live ID for accurate and fully traceable results

-- Available in three models for routine applications, sensitive measurements and complex analyses

DARMSTADT, Germany, Nov. 5, 2015 /PRNewswire/ --Merck, a leading science and technology company, has introduced Spectroquant® Prove, a new class of spectrophotometers for simplified, durable and secure analysis of waste water, drinking water, beverages and process water. Spectroquant® Prove is available in three models to meet a broad range of requirements and offers the largest choice of water test kits and methods including complete documentation.

Merck, which last month decided to drop business names such as Merck Millipore to strengthen its global brand, has been counting on innovative products to improve the value for customers and help scientists raise efficiency and effectiveness in laboratories.

"Our new Spectroquant® Prove systems unite the three most important requirements across all water applications: simplicity, security and durability," said Udit Batra, President and CEO of Merck's life science business. "With three available models, users have the flexibility to select a water analysis tool that is perfect for their individual needs and applications."

Spectroquant® Prove 100 performs Vis measurements and offers high quality and exceptional value for routine applications with Spectroquant® cell test kits.

Spectroquant® Prove 300 allows UV/Vis analyses. Its long-lasting xenon lamp makes it ideal for more intensive use. Preprogrammed free applications, like bromate and brewery tests, make it the perfect choice for drinking water and beverage testing.

Spectroquant® Prove 600 offers all the benefits of the Prove 300 system, delivers excellent resolution and sensitivity and is designed for complex analyses with high-end UV/Vis optics. The system offers a 1.8nm bandwidth and cuvettes up to 100mm. Together with the most sensitive silicate and chloride test kits, the lowest measuring ranges in process water are reached.

Spectroquant® Prove's simple design requires only a minimal amount of space and its surfaces are durable against many chemicals used in the lab. Spectroquant® Prove also allows for easy data transfers with maximum flexibility and minimal effort.

The Spectroquant® Prove family of instruments and test kits increases the efficiency and reliability of water analysis through a variety of key features, including:

  • Live ID, a new, data-rich identification system on all cell and reagent tests for transferring "live" data like expiry and lot number together with automatic, complementary calibration updates
  • Cell Test Port offers direct insertion of round cell tests without opening any lids
  • AutoSelector for Reagent Tests automatically detects the analysis method and provides all Live ID data
  • Automatic cell size recognition for rectangular cells calculates results accordingly
  • Smart Screen for simple, seamless menu navigation
  • AQA prime for exceptionally secure and easy analytical quality assurance
  • Long-life lamp, new reference beam technology minimizes the effort and costs of replacing lamps
  • Removable cell compartment, the cell holder can be removed and cleaned if something is spilled

For a high resolution image of the Spectroquant® Prove click here.

For more information about the Spectroquant® Prove click here.

About Merck

Merck is a leading science and technology company in healthcare, life science and performance materials. Around 40,000 employees work to further develop technologies that improve and enhance life - from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2014, Merck generated sales of € 11.3 billion in 66 countries.

Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck, Darmstadt, Germany holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, EMD Millipore and EMD Performance Materials.


© 2015 PR Newswire
Favoritenwechsel
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.